Urogenital symptoms: prevalence, bother, associations and impact in 22 year-old
 women of the Raine Study.

- 4 Lara Stockil: Completing Master of Clinical Physiotherapy in Women's Health and
- 5 Continence at School of Physiotherapy and Exercise Science, Curtin University. FINANCIAL
- 6 DISCLAIMER/CONFLICT OF INTEREST: NONE.
- 7 Dr Judith Thompson: Co-Coordinator Postgraduate Continence and Women's Health
- 8 Physiotherapy Program, School of Physiotherapy and Exercise Science, Curtin University.
- 9 FINANCIAL DISCLAIMER/CONFLCIT OF INTEREST: NONE.
- 10 Associate Professor Kathy Briffa: Associate Professor and Director of Research Training,
- 11 School of Physiotherapy and Exercise Science, Curtin University. FINANCIAL
- 12 DISCLAIMER/CONFLICT OF INTEREST: NONE.
- 13 Associate Professor Anne Smith: Research Fellow, School of Physiotherapy and Exercise
- 14 Science, at Curtin University. FINANCIAL DISCLAIMER/CONFLICT OF INTEREST: NONE.
- 15 Dr Darren Beales, Senior Research Fellow, School of Physiotherapy and Exercise Science,
- 16 at Curtin University FINANCIAL DISCLAIMER/CONFLICT OF INTEREST: NONE
- 17 **Professor Leon Straker**: John Curtin Distinguished Professor, School of Physiotherapy and
- 18 Exercise Science, at Curtin University and Raine Foundation Scientific Director, The Raine
- 19 Study. FINANCIAL DISCLAIMER/CONFLICT OF INTEREST: NONE
- 20 **Professor Peter O'Sullivan:** Specialist Musculoskeletal Physiotherapist (as awarded by the
- 21 Australian College of Physiotherapists, School of Physiotherapy and Exercise Science,
- 22 Curtin University. FINANCIAL DISCLAIMER/CONFLICT OF INTEREST: NONE.
- 23 Angela Jacques: Biostatistician, School of Physiotherapy and Exercise Science, Curtin
- 24 University and School of Population Health. FINANCIAL DISCLAIMER/CONFLICT OF
- 25 INTEREST: NONE.

26	LS Stockil:	Manuscript	writing, data	analysis	and interpretation
----	-------------	------------	---------------	----------	--------------------

- J Thompson: Project development, data analysis and interpretation, manuscript preparation
 and revision
- 29 K Briffa: Data analysis and interpretation, manuscript preparation and revision
- 30 A Smith: Project development, data analysis and interpretation, manuscript preparation and
- 31 revision
- 32 D Beales: Data analysis and interpretation, manuscript preparation and revision
- 33 L Straker: Data analysis and interpretation, manuscript preparation and revision
- 34 P O'Sullivan: Project development, data analysis and interpretation, manuscript preparation
- 35 and revision
- 36 A Jacques: Data management and data analysis, manuscript revision
- 37

- 38 Abstract word count: 249 words
- 39 Manuscript word count: 3720 words

41

42 **Corresponding author**

- 43 Dr Judith Thompson, School of Physiotherapy and Exercise Science, Curtin University, GPO
- 44 BoxU1987, Perth WA, 9266 9231, J.Thompson@curtin.edu.au

45

47 Abstract

48 Introduction

Urogenital symptoms are prevalent in older women but there is little data available on the
prevalence, bother, impact and associations with low back pain (LBP), obesity, parity, mental
health (MH), and quality of life (QOL) in young women.

52 **Objectives**

53 To determine the prevalence, bother and impact of urogenital symptoms, and to explore

associations with LBP, obesity, parity, MH and QOL in 22 year-old women.

55 Methods

A cross sectional evaluation using data collected from 588 women in the Raine Study, a pregnancy cohort in which participants have been regularly followed up from birth until 22 years. Data was analysed using descriptive statistics, univariate comparisons and linear regression models.

60 Results

Prevalence of urogenital symptoms were: stress urinary incontinence (SUI) 6.3%; mixed 61 urinary incontinence (MUI) 11.5%; leakage of drops 5.8%; urge urinary incontinence (UUI) 62 63 5.3%; bothersome urinary frequency 41.5%; difficulty emptying 11.8% and urogenital pain 22.9%. Urinary frequency, MUI, difficulty emptying and urogenital pain were most 64 bothersome, whilst difficulty emptying and urogenital pain were associated with greatest 65 impact. Urinary frequency, SUI, leakage of drops, difficulty emptying and urogenital pain 66 were associated with current LBP and LBP ever. Difficulty emptying and urogenital pain 67 were associated with chronic LBP. Urogenital symptoms were not associated with obesity or 68 69 parity. Women with urogenital symptoms had significantly poorer scores on Mental 70 Component Score of the SF-12 and all aspects of the Depression Anxiety Stress Score.

71 Conclusions

Urogenital symptoms are prevalent in young women, and bothersome for some. They areassociated with LBP, poorer MH and QOL.

75 Keywords

- 76 lower urinary tract symptoms; mental health; prevalence; quality of life; urinary incontinence;
- 77 urogenital pain.

78 Brief Summary

- 79 Urogenital symptoms are prevalent in young women. They are associated with low back
- 80 pain, poorer mental health and quality of life, and negative functional impact.

81 Introduction

82

83 Urogenital symptoms such as urinary incontinence (UI), lower urinary tract symptoms (LUTS) and urogenital pain have been associated with significant bother and impact, 84 85 obesity, parity, low back pain (LBP), poorer mental wellbeing and poorer quality of life (QOL) in middle aged and older women, however there is less data available pertaining specifically 86 to young women [1, 2, 4-6]. In addition, prevalence studies tend to cluster women from age 87 88 18 to the 30's, and suggest that at some point between late adolescence and early adulthood, the prevalence of UI and LUTS begins to increase, but little data is available on 89 90 the age at which this occurs, or on the factors associated with these changes, therefore more specific estimates during early adulthood may be beneficial [3, 8, 9]. Practically, 91 92 understanding this transition period may allow for improved prevention and management 93 strategies and inform when to target such measures. 94 Recent research suggests that urogenital symptoms do not occur in isolation but are 95 associated with other pain problems and mental health related factors [2]. However there is little data available for young women, and therefore detailed comorbidity patterns are not 96 established for younger women. Understanding comorbidities could assist in the design of 97 98 holistic management programs. 99 Aims

100 The first aim was to estimate the prevalence, bother and impact of urogenital symptoms

101 specifically for young women using standardised terminology and validated questionnaires.

102 The second aim was to explore associations between urogenital symptoms and LBP,

103 obesity, parity, MH and QOL in these women.

104 Materials and method

Cross-sectional evaluation was conducted using data from participants in the Western
 Australian Pregnancy Cohort (Raine) Study at the 22 year-old follow-up [17]. The Raine

107 Study started as a pregnancy cohort, and included 2868 babies at birth. Participants have

108 been followed up at regular intervals, with each follow-up including many measures of

health, disease and demographics. The cohort has retained good representativeness to thegeneral population [17].

At the 22 year-old follow-up, 1414 participants completed questionnaires investigating a
number of health elements including: urogenital symptoms; current and past history of LBP;
parity; MH and QOL; and a physical examination where height and weight were measured.
Of the 1414 participants, 607 were women and were therefore included in this study.
This project was approved by the Raine Study Executive Committee. Ethical approval was

obtained through Curtin University (RDHS-122-15).

117 <u>Measures</u>

The seven urogenital symptoms assessed were: UI; SUI; UUI; MUI; bothersome urinary 118 119 frequency; difficulty emptying the bladder and urogenital pain. A combined estimate of 120 prevalence and bother were measured using the Urogenital Distress Inventory-Short Form 121 (UDI-6) which has established reliability and validity [18]. The participants were asked the 122 following questions: 'Do you experience, and, if so, how much are you bothered by: 1. Frequent urination? (bothersome urinary frequency) 2. Urine leakage related to feeling of 123 urgency? (Urinary urge incontinence) 3. Urine leakage related to physical activity, coughing 124 125 or sneezing? 4. Small amounts of urine leakage (drops)? 5. Difficulty emptying your bladder? 6. Pain or discomfort in the lower abdomen/genital area?' (urogenital pain). A 126 urogenital symptom was considered to be present and bothersome when a response of 127 slightly, moderately or greatly was given to any one of the questions. 128 SUI was defined when a response of either slightly, moderately or greatly was given to 129 leaking urine related to physical activity, coughing or sneezing. Although small amounts of 130 urine leakage (drops) is considered as a stress symptom in terms of the UDI-6, potentially it 131 could be any form of UI and therefore in this study it was analyzed separately. MUI was 132 considered when a response of either slightly, moderately or greatly was given to question 2 133

134 (UUI) and question 3 (SUI) or question 4 (leakage of drops).

The pelvic floor impact questionnaire- short-form 7 (PFIQ-7) has established validity and
reliability for assessing the impact of urogenital symptoms on QOL in women [19]. Seven

questions ask if urinary problems/pain or discomfort have affected ability to do household
chores, physical activities, entertainment activities, travel, participate in social activities,
emotional health and frustration [20]. For this study the responses were scored as follows:
not at all=0; slightly=1; greatly and moderately were scored together due to low numbers=2.
Scores were added, with a minimum score of 0 indicating no impact and 14 indicating
maximal impact.

143 LBP prevalence was measured using questions from the modified Nordic Questionnaire 144 which is both valid and reliable [21]. LBP was classified as: chronic (positive response to 145 'Has your low back pain ever lasted for more than three months continuously?' and/or 146 positive response to 'Has your low back pain ever lasted for more than three months off and 147 on?'); current (positive response to 'Has your low back been painful at any time in the last 148 month?') and ever (positive response to 'Have you ever had low back pain?'). BMI, was 149 calculated as weight (kilograms) divided by height (meters) squared, both being reliable and 150 valid [22]. Women were classified as underweight (BMI < 18.5); normal weight (BMI 18.5-<25), overweight (BMI \geq 25-<30) or obese (BMI \geq 30) [23]. Parity was ascertained by 'Do you 151 have any biological children?' (no=nulliparous, yes=parous). MH was assessed using the 152 153 short-form Depression Anxiety Stress Scale (DASS-21), a valid and reliable measure of depression, anxiety and stress [24]. QOL was measured using the Short Form 12 Health 154 Survey (SF-12), which consists of twelve questions assessing physical and mental 155 wellbeing. It is valid and reliable for assessing QOL in women [25]. Separate physical and 156 mental component scores were calculated, standardised to a mean of 50 (SD = 10), with 157 higher scores indicating better QOL [25]. 158

159 Statistical analysis

Aim 1: For each urogenital symptom, prevalence for the presence of a bothersome symptom was estimated. Proportions of women with slight and moderate/great bother, and with slight (PFIQ-7=1-7) or moderate/great impact (PFIQ-7 >7-14), were calculated. In addition, a binary variable was derived denoting the prevalence of having at least one or more symptoms assessed.

Aim 2: To examine the associations between each urogenital symptom and LBP, obesity,
parity, mental health and QOL, a series of logistic regressions were estimated. Each
urogenital symptom was considered as the dependent variable, with the reference group
being those without any urogenital symptoms.

Mental health measures (DASS depression, anxiety and stress subscales) displayed skewed 169 distributions and were parametrised in logistic regression models as ordinal (categories none 170 171 (z score >0.5), mild (z-score 0.5-1.0), moderate (z score 1.0 -2.0) severe (z score 2.0-3.0), 172 extremely severe (z score >3.0) [26] where numbers permitted, or as a binary variable categories (none or mild versus, moderate or more) to avoid empty or sparse cells for 173 174 urogenital symptoms with low prevalence. Estimates for mental health (DASS-21) and QOL (SF12) were adjusted for the presence of current LBP in instances where the urogenital 175 symptom was associated with this potential confounder. Odds ratios with associated 95% 176 confidence intervals and p-values are presented. 177

Data were analysed using IBM SPSS version 24.0 (Armonk, NY). P-values <0.05 were
 considered statistically significant.

180 Results

181 Of the 607 women completing the 22 year follow-up questionnaire, 581/607 (95.6%)

provided valid responses for all six questions assessing the presence of the seven urogenital

symptoms, whilst 588 (96.7%) provided a valid response to one or more of the six questions.

184 Sample characteristics are shown in Table 1.

185 Participants reporting at least one current bothersome urogenital symptom were 334/581

186 (57.5%). The most prevalent type of UI was MUI (11.5%), followed by SUI (6.3%), small

drops of leakage (5.8%), and UUI (5.3%). Prevalence of bothersome urinary frequency was

- 188 41.5%, however the majority of these women (62.7%) reported only slight bother (Table 2).
- 189 Prevalence of bothersome urinary frequency at moderate/great levels was 15.5%. The
- 190 urogenital symptoms that were most bothersome (moderate to great bother) were urogenital

pain 47/134 (64.9%), frequency 91/244 (37.3%), MUI 22/67 (32.8%), and difficulty emptying
the bladder with 17/69 (24.6%). In terms of UI, MUI was more bothersome than SUI or UUI
(Table2).

194 Urogenital symptoms associated with the greatest impact on QOL of young women were

difficulty emptying the bladder 7/67 (10.4%) and urogenital pain 10/131 (7.6%) (Table 2).

196 Although the majority of women with each symptom did not report any level of impact (i.e.

197 PRIQ-7=0), slight impact was reported by at least a third of all the young women

198 experiencing each symptom (Table 2).

199 Table 3 presents odds ratios for the presence of urogenital symptoms according to LBP,

200 obesity, parity, and mental/physical health status. The presence of at least one urogenital

symptom was strongly associated with LBP ever (Table 3). LBP ever and current LBP were

also significantly associated with urinary frequency, SUI, leakage of drops, difficulty

203 emptying and urogenital pain. Chronic LBP was associated with difficulty emptying the

204 bladder and urogenital pain (Table 3).

There were no associations between obesity or parity and any urogenital symptoms (Table3).

207 Higher levels of depression, anxiety and stress were significantly associated with the

208 presence of at least one urogenital symptom and also with frequency, MUI, difficulty

209 emptying and pain (Table 3).

Lower levels of mental component score were associated with the presence of at least one urogenital symptom and with frequency, MUI, difficulty emptying and pain. Lower levels of physical component score were not significantly associated with urogenital symptoms (Table

213 3).

214 Discussion

215 **Prevalence**

This study found that the prevalence of any UI in young, predominantly nulliparous women to be between 5.3% and 11.5%. This is higher than the reported prevalence of 0.3% for UI in 15-17 year olds [4], but is lower than the prevalence range of 9.3%-20.4% currently reported

219 for women aged younger than 30 [3, 8, 9]. Prevalence data has previously been reported for 220 mixed aged groups of women: 15-25 years [8], 16-30 [3] and 18-29 [9], whilst the women in this study were all aged 22 years. This may account for the lower prevalence. It is possible 221 that at age 22, the downward trend of UI seen in children and adolescents has begun to turn 222 223 upwards. The prevalence of the main subtypes of UI in this study were SUI 6.3%, UUI 5.3% and MUI 11.5%. The prevalence of SUI and UUI are consistent with the prevalence ranges 224 225 currently reported in the literature for women aged younger than 30, SUI 5.9%-7.7% and UUI 226 3.4%-9% [3, 8, 9].

227 However, the prevalence of MUI is much higher in this study than the current prevalence 228 range of MUI 1.9%-5.4% in women aged younger than 30 [3, 8, 9]. This may be due to the 229 way MUI was defined in the questionnaires used in each of the studies. In the present study, 230 the UDI-6 was used to measure prevalence of UI subtypes, and leakage of drops of urine 231 was included in MUI which may have contributed to the higher prevalence. 'Leakage of 232 drops' was analysed separately to SUI as the researchers were not sure that all women 233 reporting leakage of small drops of urine had SUI. However, the results show that leakage of drops and SUI behave in a similar way and therefore it is likely that young women are 234 235 reporting SUI as leakage of drops. Current literature suggests that the severity of UI increases with increasing age [4] and given that between 5.3% and 11.5% of the young adult 236 women in our study are already experiencing a form of UI, screening younger women for UI 237 would give an opportunity for early intervention. 238

LUTS such as bothersome urinary frequency, difficulty emptying the bladder and urogenital 239 pain were prevalent in young women, with 41.5% reporting urinary frequency, 11.8% 240 reporting difficulty emptying the bladder and 22.9% reporting urogenital pain. These 241 prevalence ranges are higher than those reported in literature for women aged younger than 242 39, frequency 7.9% - 9.5%, difficulty emptying the bladder 0.6%-6.0% and bladder pain 3.9% 243 [11, 12]. However, comparing these results is difficult as different questionnaires and 244 definitions were used. Definitions used for daytime urinary frequency may be based on the 245 246 responder's perception of whether they void too often per day (as recommended by the

247 International Continence Society) or alternatively on a threshold number of voids per day (Irwin et al 2008). One study [11] used a responder's perception based definition "the 248 complaint that micturition occurs more frequently than previously deemed normal by the 249 woman" [10], whilst the other defined urinary frequency as more than 8 voids per day [12]. 250 251 The UDI-6 used for the present study includes a responder's perception type question where 252 the young women were asked if they experienced urinary frequency and if so, how much 253 were they bothered by it. No data were collected on the number of voids per day or fluid 254 intake. Irwin et al (2008) compared prevalence of ICS defined frequency (responder 255 perception) with a numerical threshold of more than 8 voids per day in a population-based 256 sample. They found the prevalence of urinary frequency was higher using the perception 257 definition than using the numerical threshold definition (25% versus 19% of women with 258 overactive bladder) [28]. This may, in part, explain the higher prevalence of frequency in our 259 sample. Nonetheless, further research into the number of day voids and fluid intake in 260 young Australian women is recommended to obtain a better understanding of urinary 261 frequency in this group and whether it is related to higher fluid intake or other lifestyle factors. 262

263 For difficulty emptying the bladder, the young women in the present study were asked whether they experienced and if so were they bothered by difficulty emptying the bladder. In 264 other studies the International Continence Foundation definitions are used, in which difficulty 265 emptying the bladder is described more specifically such as straining, hesitancy, 266 intermittency or slow stream, which may explain the higher numbers in this study [10-12]. 267 The pain definition used in the present study was guite broad, 'pain or discomfort in the 268 lower abdomen/genital area', whereas in other studies women were asked about bladder 269 pain, hence the likely reason for the higher prevalence in this study. In addition, a recent 270 271 study reported the prevalence of severe menstrual pain in this same cohort of young women 272 aged at 20 and 22 years to be 17% [27]. Further investigation of urogenital pain and 273 menstrual pain in the cohort may be useful, given there could be potential shared underlying 274 pain mechanisms.

275 Bother and Impact

276 Urogenital pain, urinary frequency and difficulty emptying the bladder were found to be most bothersome by the young women in this study, and MUI was found to be more bothersome 277 than SUI and UUI. Urogenital symptoms associated with the greatest impact on the QOL of 278 279 young women were difficulty emptying the bladder and urogenital pain, which is similar to current literature including older women [1, 5, 6]. In terms of impact, at least a third of all the 280 281 young women who reported having each urogenital symptom reported slight impact on their 282 ability to perform simple daily activities. Whilst this proportion is fairly small, it is important to remember the young age of these women, and that the tasks being affected are normal 283 284 activities of daily living such as shopping, entertaining and household chores. Previous 285 studies have found that UI in young women is also associated with adverse impact on daily 286 life such as limiting fluid intake, wearing pads due to fear of odour, as well as poorer overall 287 well-being [3, 8].

288 Correlates of urogenital symptoms

289 Lower back pain

290 Strong associations were identified between the presence of at least one urogenital 291 symptom and both LBP ever and current LBP, with SUI and leakage of drops being associated with current LBP and a history of LBP ever. This appears consistent with the 292 finding that pre-existing and/or new onset UI or LBP can be associated with a higher risk of 293 developing LBP or UI respectively. [13]. The associations between LBP and UI are likely to 294 be complex and are not yet fully understood. It has been suggested that sensorimotor 295 changes linked to altered motor control of muscles including the abdominal, back and PFM, 296 known to be associated with a history of LBP and UI, may underpin this relationship [13]. 297 In addition, there were strong associations between difficulty emptying the bladder and 298 urogenital pain with current, chronic and LBP ever. This comorbidity of urogenital pain and 299 musculoskeletal LBP may relate to shared musculature, or shared underlying pain 300 mechanisms [14]. In this study, urogenital pain was considered as any pain in the lower 301

abdominal or genital area, and as such it is possible that this included some LBP, thusconfounding the data.

304 Obesity

Obesity was more strongly associated with SUI and leakage of small drops of urine 305 306 (although not significant) than with any of the other urogenital symptoms. This may be due to 307 a lack of power as only 17% of the sample were classified as obese. A sensitivity analysis did not identify significant associations either. These results are consistent with another 308 309 study which reported no association between UI and BMI in young nulligravid women [3]. 310 However, there is existing strong evidence to suggest that obesity increases intra-abdominal 311 pressure which then predisposes SUI [4], and that women who become obese at a younger 312 age are at a higher risk of developing UI in middle age [4, 29]. In light of this, it is 313 recommended that young women are given advice and education on the risks associated 314 with being obese, strategies to help reduce their BMI and referred on for early diagnosis and 315 treatment of SUI. There is good evidence that both reducing BMI and simple, safe 316 treatments like pelvic floor muscle training can effectively treat and reduce the symptoms of SUI [4]. The prospective nature of the Raine study means that additional data on the 317 318 association between obesity and urogenital symptoms can be gathered as these women 319 age.

320 Parity

There was no association between parity and UI, which may be due to the very low number 321 of parous women in our study (6.1%) thereby reducing the power, or because most of the 322 parous women had only one baby. However, parity is an established risk factor for UI, with 323 increasing parity being associated with increased risk of UI, and this association is strongest 324 for women aged in their thirties and forties [4]. The underlying mechanisms of exactly how 325 pregnancy and childbirth predispose UI are still not fully understood [4]. Current research 326 327 suggests pelvic floor dysfunction may occur as a result of trauma to the muscles, connective 328 tissue, nerves or blood supply during vaginal birth, which can then predispose women to UI 329 [4]. It is possible that parity and obesity were not found to be associated with urogenital

symptoms in this study due to the relatively young, same aged (all 22 years old) mostly
nulliparous sample. Previous studies finding associations have been in older or mixed age
samples, and it may be that the influence of BMI becomes greater with age and parity.

The results suggest significantly poorer DASS and SF-12 scores in young women with

333 Mental health and quality of life

334

335 urogenital symptoms as opposed to those without urogenital symptoms, even after adjustment for comorbid LBP. However, the mean SF-12 scores for the young women with 336 urogenital symptoms were within one standard deviation of the population mean (PCS=52.6; 337 MCS=43.7), and the difference in these scores between those with and without urogenital 338 symptoms was, although statistically significant, only 1.6 and 2.7 points respectively. 339 Therefore, the clinical relevance of the association between urogenital symptoms, 340 particularly urogenital pain, and poorer MH in young women, is difficult to ascertain. Previous 341 studies that have reported an association between urogenital symptoms and poorer MH and 342 343 QOL in middle aged and older women [4-6], and therefore it would be recommended that any young women presenting with urogenital symptoms are screened for MH and QOL. The 344

prospective nature of the Raine study may provide insight into these associations in futurefollow-up studies.

Our results also showed an association between MUI and higher depression, anxiety and stress scores, which is in accordance with previous studies which included middle and older ages women [5, 30]. An association between UI and depression, and MUI and anxiety have been reported in the literature, however the underlying mechanisms for the observed associations are complex and not yet fully understood [4, 5].

352 Significance and implications

The results indicate that urogenital symptoms are prevalent and bothersome in young women, and are associated with significant impact including poorer MH and QOL. Research has shown that many women who experience urogenital symptoms do not seek help [7], and that younger women have little insight into their urogenital health [8]. It is therefore recommended that primary prevention programs are developed such as community-based

358 education sessions, and that health professionals screen young women for urogenital symptoms and impact during routine episodes of care. Whilst there is Level 1 evidence that 359 simple, safe, cost-effective treatments such as pelvic floor muscle training are effective for 360 treating and reducing urogenital symptoms [31], optimal management of urogenital 361 362 symptoms requires a multidimensional view which considers physical health, LBP history, MH and QOL to minimise impact on young women. The Raine Study is a prospective study 363 and as such there is great potential for further follow up of these women to obtain more 364 365 detailed information and data on trajectories of urogenital symptoms and associated factors. 366 This study involved a community sample of women of the same age, thus minimising 367 selection bias.

368 Limitations of study and Recommendations

The urogenital symptoms were based on self-report by the participants, and therefore there is potential for misclassification, especially for those who reported leakage of small drops of urine. Not all young women were able to attend the physical examination, and therefore numbers available for estimation of the association BMI with urogenital symptoms were smaller.

374 As this is a cross-sectional evaluation, the findings are associations and no causality can be drawn. Further research is recommended to establish: the prevalence of other types of UI in 375 young women, (such as post micturition dribble and passive incontinence which are not 376 included in the UDI-6); to study specific pain syndromes such as bladder pain syndrome, 377 chronic pelvic pain and urethral pain syndrome; and to determine the direction and 378 underlying mechanisms of the associations between urogenital symptoms and QOL and MH 379 in young women. A limitation of the study is that the association of sexual activity with 380 urogenital symptoms was not assessed, as sexually active women may be at a higher risk of 381 having lower urinary tract symptoms. 382

383 Conclusion

384 Urogenital symptoms are both prevalent and bothersome in some young women. They are
385 associated with LBP, poorer MH and QOL, and functional impacts.

386 Acknowledgements and funding

We would like to acknowledge the Raine Study participants for their ongoing participation in 387 the study, the families of the Raine Study participants, the Raine Study Team for study co-388 389 ordination and data collection, the UWA Centre for Science for utilisation of the facility and the Sleep Study Technicians. We would like to acknowledge the University of Western 390 Australia (UWA), Curtin University, the Raine Medical Research Foundation, the UWA 391 Faculty of Medicine, Dentistry and Health Sciences, the Telethon Kids Institute, the 392 Women's and Infant's Research Foundation (King Edward Memorial Hospital), Edith Cowan 393 University, Murdoch University and University of Notre Dame for providing funding for the 394 Core Management of the Raine Study. The 22 year Raine Study follow-up was funded by 395 396 NHMRC project grants 1027449, 1044840 and 1021855. Funding was also generously 397 provided by Safework Australia. 398 Conflicts of Interest: None.

400 References

- 4011.Abrams, P., A.P. Smith, and N. Cotterill, The impact of urinary incontinence on health-related402quality of life (HRQoL) in a real-world population of women aged 45–60 years: results from a403survey in France, Germany, the UK and the USA. BJU International, 2015. 115(1): p. 143-152.
- 404
 2.
 Engeler, D., et al. EAU GUIDELINES ON CHRONIC PELVIC PAIN. 2016 [cited 2016

 405
 21/02/2017].
- 406 3. O'Halloran, T., et al., *Urinary Incontinence in Young Nulligravid Women*. Annals of Internal
 407 Medicine, 2012. **157**: p. 87-93.
- 408 4. Milsom, I., et al., *Committee 1: Epidemiology of Urinary Incontinence (UI) and other Lower*409 *Urinary Tract Symptoms (LUTS), Pelvic Organ Prolapse (POP) and Anal Incontinence (AI),* in
 410 *Incontinence. 5th International Consultation on Incontinence,* P. Abrams, et al., Editors. 2013,
 411 ICUD-EAU: Paris. p. 15-107.
- 412 5. Coyne, K.S., et al., Urinary Incontinence and its Relationship to Mental Health and Health413 Related Quality of Life in Men and Women in Sweden, the United Kingdom, and the United
 414 States. European Urology, 2012. 61(1): p. 88-95.
- 6. Clemens, J.Q., et al., *Prevalence of Painful Bladder Symptoms and Effect on Quality of Life in*Black, Hispanic and White Men and Women. The Journal of Urology, 2007. **177**(4): p. 13901394.
- 4187.Lasserre, A., et al., Urinary Incontinence in French Women: Prevalence, Risk Factors, and419Impact on Quality of Life. European Urology, 2009. 56(1): p. 177-183.
- 8. Bardino, M., et al., *Frequency and Determinants of Urinary Incontinence in Adolescent and Young Nulliparous Women.* Journal of Pediatric and Adolescent Gynecology, 2017. 28(6): p.
 462-470.
- 423 9. Schreiber Pedersen, L., et al., *Prevalence of urinary incontinence among women and analysis*424 of potential risk factors in Germany and Denmark. Acta Obstet Gynecol Scand, 2017.
- Haylen, B., et al., *An International Urogynecological Association (IUGA) / International Continence Society (ICS) Joint Report on the Terminology for Female Pelvic Floor Dysfunction.*Neurourology and Urodynamics, 2010. 29: p. 4-20.
- Irwin, D.E., et al., *Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study.* European
 Urology, 2006. 50(6): p. 1306-1315.
- 431 12. van Breda, H.M.K., J.L.H.R. Bosch, and L.M.O. de Kort, *Hidden prevalence of lower urinary*432 *tract symptoms in healthy nulligravid young women.* International Urogynecology Journal,
 433 2015. 26(11): p. 1637-1643.
- 434 13. Smith, M.D., A. Russell, and P.W. Hodges, *The relationship between incontinence, breathing*435 *disorders, gastrointestinal symptoms, and back pain in women: a longitudinal cohort study.*436 Clin J Pain, 2014. **30**(2): p. 162-7.
- 437 14. Beales D and O.S. P., A person-centred biopsychosocial approach to assessment and
 438 management of pelvic girdle pain., in Grieve's Modern Musculoskeletal Physiotherapy. .
 439 2015, Elsevier Health Sciences: London, UK. p. 488-495.
- 440 15. Ghaderi, F., et al., *Effects of Stabilization Exercises Focusing on Pelvic Floor Muscles on Low*441 *Back Pain and Urinary Incontinence in Women.* Urology, 2016.
- Hunskaar, S., A systematic review of overweight and obesity as risk factors and targets for
 clinical intervention for urinary incontinence in women. Neurourol Urodyn, 2008. 27(8): p.
 749-57.
- 445 17. Straker L, et al., *Cohort Profile: The Western Australian Pregnancy Cohort (Raine) Study-*446 *Generation 2.* Int J Epidemiol., 2017.
- 447 18. Uebersax, J.S., et al., Short forms to assess life quality and symptom distress for urinary
 448 incontinence in women: The incontinence impact questionnaire and the urogenital distress
 449 inventory. Neurourology and Urodynamics, 1995. 14(2): p. 131-139.

- 450 19. Staskin, D., et al., Initial Assessment of Urinary Incontinence in Adult Male and Female 451 Patients (5A) Patient-Reported Outcome Assessment (5B), in Incontinence. 5th International 452 Consultation on Incontinence, P. Abrams, et al., Editors. 2013, ICUD-EAU: Paris. p. 361-428. Barber, M.D., M.D. Walters, and R.C. Bump, Short forms of two condition-specific quality-of-453 20. 454 life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). American 455 Journal of Obstetrics and Gynecology, 2005. 193(1): p. 103-113. 456 21. Dionne, C.E., et al., A consensus approach toward the standardization of back pain definitions for use in prevalence studies. SPINE, 2008. 33(1): p. 95-103. 457 458 Romero-Corral, A., et al., Accuracy of Body Mass Index to Diagnose Obesity In the US Adult 22. Population. International journal of obesity (2005), 2008. 32(6): p. 959-966. 459 460 23. World Health Organization. BMI classification. 2016 [cited 2016 15 June 2016]. 461 24. Henry, J.D. and J.R. Crawford, The short-form version of the Depression Anxiety Stress Scales 462 (DASS-21): construct validity and normative data in a large non-clinical sample. Br J Clin 463 Psychol, 2005. 44(Pt 2): p. 227-39. 464 25. Ware, J.E., Jr., M. Kosinski, and S.D. Keller, A 12-Item Short-Form Health Survey: Construction 465 of Scales and Preliminary Tests of Reliability and Validity. Medical Care, 1996. 34(3): p. 220-466 233. 467 26. Lovibond, S.H. and P.F. Lovibond, Manual for the depression anxiety stress scales. Psychology 468 Foundation, 1995. 469 27. Slater, H., et al., Heightened cold pain and pressure pain sensitivity in young female adults 470 with moderate-to-severe menstrual pain. PAIN, 2015. **156**(12): p. 2468–2478. 471 Irwin, D., et al., EPIC Study Group. Symptom bother and health care-seeking behavior among 28. 472 individuals with overactive bladder. . European Urology, 2008. 53(5): p. 1029-37. 473 29. Mishra, G., et al., Body weight through adult life and risk of urinary incontinence in 474 middleaged women: results from a British prospective cohort. International Journal of 475 Obesity, 2008. 32(9): p. 1415–1422. 476 30. Felde, G., I. Bjelland, and S. Hunskaar, Anxiety and depression associated with incontinence 477 in middle-aged women: a large Norwegian cross-sectional study. International 478 Urogynecology Journal, 2012. 23(3): p. 299-306. 479 31. Moore, K., et al., Adult Conservative Management, in Incontinence: 5th International 480 Consultation on Incontinence, . 2013, ICUD-EAU: Paris.
- 481

Table 1: Response rates and sample characteristics

Correlates	Number providing data N (%)	Number affected N (%)
Low back pain		
LBP ever	585 (99.5)	406 (69.4)
LBP current	583 (99.1)	308 (52.8)
LBP chronic	583 (99.1)	225 (38.6)
BMI ^a	478 (81.3)	
Underweight		22 (4.6)
Normal		284 (59.4)
Overweight		89 (18.6)
Obese		83 (17.4)
Parity	588 (100)	
Nulliparous		230 (93.1)
DASS-21		
Depression	583 (99.1)	
None		380 (65.2)
Mild		73(12.5)
Moderate		65 (11.2)
Severe		32 (5.5)
Extremely severe		33 (5.7)
Anxiety	582 (98.9)	
None		412 (70.8)
Mild		41(7.0)
Moderate		75 (12.9)
Severe		27 (4.6)
Extremely severe		27 (4.6)
Stress	581 (98.8)	
None		432 (74.4)
Mild Madavata		45 (7.8)
Nioderate		53 (9.1) 27 (6.4)
Severe Extromoly covere		57 (0.4) 14 (2.4)
SE-12 ^b	572 (07 1)	14 (2.4)
Dhysical component score	575 (57.4)	53 3 (7 2)
Mental component score		<i>44</i> 8 (10 7)
iviental component score		44.8 (10.7)

^b The physical and mental component scores are reported as mean (SD)

^a BMI was not measured for 110 women (18.7%) as they did not attend the physical examination. Women were classified as either obese (BMI ≥30) or non-obese (BMI<30) in regression models.

Urogenital	Presence of	Severity o	of Bother ^a	Level of impact ^b		
symptom	symptom	N (% of those wi	ith the symptom)	N (% of those with the		
	sample)			Sym	ptom	
	Yes	Slight	Moderate/	Slight	Moderate	
			Great	(1-7)	(>7)	
	n	n	n	Ν	Ν	
	(%)	(%)	(%)	%	%	
Frequency	244 of 588	153 of 244	91 of 244	86 of 237	8 of 237	
	(41.5)	(62.7)	(37.3)	(36.3)	(3.4)	
UUI	31 of 583	26 of 31	5 of 31	11 of 30	0 of 30	
	(5.3)	(83.9)	(16.1)	(36.7)	(0.0)	
SUI	37 of 583	34 of 37	3 of 37	14 of 37	1 of 37	
	(6.3)	(91.9)	(8.1)	(37.8)	(2.7)	
MUI	67 of 583	45 of 67	22 of 67	26 of 66	5 of 66	
	(11.5)	(67.2)	(32.8)	(39.4)	(7.6)	
Leakage of	34 of 583	30 of 34	4 of 34	13 of 33	0 of 33	
small drops	(5.8)	(88.2)	(11.8)	(39.4)	(0.0)	
Difficulty	69 of 584	52 of 69	17 of 69	31 of 67	7 of 67	
emptying bladder	(11.8)	(75.4)	(24.6)	(46.3)	(10.4)	
Pain	134 of 584	87 of 134	47 of 134	62 of 131	10 of 131	
	(22.9)	(64.9)	(35.1)	(47.3)	(7.6)	

Table 2: Prevalence, bother and level of impact associated with urogenital symptoms. 496

497 UUI urinary urge incontinence, SUI stress urinary incontinence, MUI mixed urinary incontinence, leakage of small drops 498 small drops of urinary leakage

499 Of the 607 women who completed the 22 year follow-up questionnaire, 581/607 (95.6%) provided valid responses for all 6 500 questions of the UDI-6), whilst 588 (96.7%) provided a valid response to one or more of the 6 questions.

501 ^a The level of bother was calculated from responses to the UDI-6 and is therefore only given for women who had the particular 502 urogenital symptom. Percentage of subjects with presence of stated urogenital symptom

503 ^b The level of impact was calculated from responses to the PFIQ-7and therefore is only given for the women who had the

504 505 particular urogenital symptom. Percentage of subjects with presence of stated urogenital symptom.

Table 3: Comparisons of LBP, obesity, parity, mental and physical health in those 588 participants who provided a valid response to the UDI-6
 .

	No	At least one UG		Frequency		UUI		SUI		
	Symptoms	symptom								
	n= 247ª	n=334ª	OR	n=244ª	OR	n=31ª	OR	n=37ª	OR	
			95% CI		95% CI		95% CI		95% CI	
			p-value		p-value		p-value		p-value	
LBP ever	151	248	1.82*	181	1.82*	18	0.86	31	3.22*	
	(61.6%)	(74.5%)	1.27-	(74.5%)	1.23-	(58.1%)	0.40-	(83.8%)	1.29-	
			2.59*		2.68*		1.84		8.00*	
			.001*		.002*		.701		.012*	
LBP current	108	194	1.77*	137	1.64*	14	1.04	24	2.32*	
	(44.3%)	(58.4%)	1.27-	(56.6%)	1.15-	(45.2%)	0.49-	(64.9%)	1.13-	
			2.47*		2.35*		2.20		4.78*	
			.001*		.007*		.924		.022*	
LBP chronic	83	136	1.33	104	1.44	7	0.56	16	1.47	
	(34.2%)	(40.8%)	0.94-	(42.8%)	1.00-2.08	(22.6%)	0.23-	(43.2%)	0.73-	
			1.88		.051		1.36		2.96	
			.103				.201		.283	
Obese	32	51	1.14	33	0.99	4	1.01	9	1.90	
(BMI>30)	(16.5%)	(18.4%)	0.70-	(16.3%)	0.58-1.68	(16.7%)	0.32-	(27.3%)	0.81-	
			1.86		.966		3.16		4.46	
			.591				.983		.142	
Nulliparous	230	315	1.23	230	1.21	28	0.69	33	0.61	
	(93.1%)	(94.3%)	0.63-	(94.3%)	0.58-2.52	(90.3%)	0.19-	(89.2%)	0.19-	
			2.42		.602		2.50		1.92	
			.556				.572		.399	
DASS depression	46	83	1.19 ^{*b,c}	66	1.21* ^{b,c}	6	1.08 ^e	12	1.92 ^{c,e}	
(moderate or	(18.8%)	(25.1%)	1.03-	(27.3%)	1.03-	(20.0%)	0.42-	(32.4%)	0.89-	
more)			1.38*		1.41*		2.80		4.15	
			.018*		.019*		.872		.099	
DASS anxiety	37	90	1.26* ^{b,c}	68	1.28* ^{b,c}	6	1.34 ^e	8	1.32 ^{c,e}	

(moderate or more)	(15.2%)	(27.2%)	1.07- 1.47* .004*	(28.2%)	1.08- 2.13* .004*	(20.0%)	0.52- 3.50 .546	(21.6%)	0.55- 3.19 .531
DASS stress	31	71	1.28* ^{b,c}	54	1.30* ^{b,c}	6	1.64 ^e	5	1.08 ^{c,e}
(moderate or	(12.8%)	(21.5%)	1.07-	(22.3%)	1.08-	(20.0%)	0.62-	(13.9%)	0.39-
more)			1.52*		1.56*		4.32		3.03
			.006*		.005*		.315		.878
SF12 PCS	54.2	52.6	0.98 ^{c,d}	52.5	0.98 ^{c,d}	53.0	0.98 ^d	54.0	1.01 ^{c,d}
(mean, SD)	(6.6)	(7.5)	0.95-	(7.9)	0.95-1.00	(6.1)	0.93-	(6.9)	0.96-
			1.00		.067		1.03		1.06
			.069				.383		.796
SF12 MCS	46.5	43.6	0.98 ^{*c,a}	43.5	0.98 ^{*c,a}	43.9	0.98 [°]	42.0	0.97 ^{c,a}
(mean, SD)	(10.7)	(10.6)	0.96-	(10.8)	0.96-	(10.8)	0.95-	(12.4)	0.94-
			0.99*		0.99*		1.01		1.00
	No	Δ.	.005*	(ma	.008* Il dronc	Difficulty	.214	Da	.066 in
	Symptoms	IV	101	SILIA	nurops	Difficulty	Emptying	Pd	IN
	Symptoms								
	n= 247ª	n=67ª	OR	n=34ª	OR	n=69ª	OR	n=134ª	OR
	n= 247 ^a	n=67ª	OR 95% CI	n=34ª	OR 95% CI	n=69ª	OR 95% CI	n=134ª	OR 95% CI
	n= 247 ^a	n=67ª	OR 95% CI p-value	n=34ª	OR 95% CI p-value	n=69ª	OR 95% CI p-value	n=134ª	OR 95% CI p-value
LBP ever	n= 247 ^a	n=67ª 46	OR 95% CI p-value 1.36	n=34 ^a 31	OR 95% CI p-value 6.43*	n=69ª 54	OR 95% CI p-value 2.24*	n=134ª 107	OR 95% CI p-value 2.47*
LBP ever	n= 247 ^a 151 (61.6%)	n=67ª 46 (68.7%)	OR 95% CI p-value 1.36 0.77-	n=34ª 31 (91.2%)	OR 95% CI p-value 6.43* 1.91-	n=69ª 54 (78.3%)	OR 95% CI p-value 2.24* 1.20-	n=134ª 107 (79.9%)	OR 95% CI p-value 2.47* 1.50-
LBP ever	n= 247 ^a 151 (61.6%)	n=67ª 46 (68.7%)	OR 95% CI p-value 1.36 0.77- 2.43	n=34ª 31 (91.2%)	OR 95% CI p-value 6.43* 1.91- 21.63*	n=69ª 54 (78.3%)	OR 95% CI p-value 2.24* 1.20- 4.20*	n=134ª 107 (79.9%)	OR 95% CI p-value 2.47* 1.50- 4.04*
LBP ever	n= 247 ^a 151 (61.6%)	n=67ª 46 (68.7%)	OR 95% CI p-value 1.36 0.77- 2.43 .292	n=34ª 31 (91.2%)	OR 95% CI p-value 6.43* 1.91- 21.63* .003*	n=69ª 54 (78.3%)	OR 95% CI p-value 2.24* 1.20- 4.20* .012*	n=134ª 107 (79.9%)	OR 95% CI p-value 2.47* 1.50- 4.04* <.001*
LBP ever LBP current	n= 247 ^a 151 (61.6%) 108	n=67 ^a 46 (68.7%) 35	OR 95% CI p-value 1.36 0.77- 2.43 .292 1.38	n=34 ^a 31 (91.2%) 26	OR 95% CI p-value 6.43* 1.91- 21.63* .003* 1.09*	n=69 ^a 54 (78.3%) 43	OR 95% CI p-value 2.24* 1.20- 4.20* .012* 2.08*	n=134ª 107 (79.9%) 87	OR 95% CI p-value 2.47* 1.50- 4.04* <.001* 2.33*
LBP ever LBP current	n= 247 ^a 151 (61.6%) 108 (44.3%)	n=67 ^a 46 (68.7%) 35 (52.2%)	OR 95% CI p-value 1.36 0.77- 2.43 .292 1.38 0.80- 2.27	n=34 ^a 31 (91.2%) 26 (76.5%)	OR 95% CI p-value 6.43* 1.91- 21.63* .003* 1.09* 1.78- 2.40*	n=69 ^a 54 (78.3%) 43 (62.3%)	OR 95% CI p-value 2.24* 1.20- 4.20* .012* 2.08* 1.20- 2.60*	n=134 ^a 107 (79.9%) 87 (64.9%)	OR 95% CI p-value 2.47* 1.50- 4.04* <.001* 2.33* 1.51- 2.60*
LBP ever LBP current	n= 247 ^a 151 (61.6%) 108 (44.3%)	n=67 ^a 46 (68.7%) 35 (52.2%)	OR 95% CI p-value 1.36 0.77- 2.43 .292 1.38 0.80- 2.37	n=34 ^a 31 (91.2%) 26 (76.5%)	OR 95% CI p-value 6.43* 1.91- 21.63* .003* 1.09* 1.78- 9.40*	n=69 ^a 54 (78.3%) 43 (62.3%)	OR 95% CI p-value 2.24* 1.20- 4.20* .012* 2.08* 1.20- 3.60*	n=134ª 107 (79.9%) 87 (64.9%)	OR 95% CI p-value 2.47* 1.50- 4.04* <.001* 2.33* 1.51- 3.60*
LBP ever LBP current	n= 247 ^a 151 (61.6%) 108 (44.3%)	n=67 ^a 46 (68.7%) 35 (52.2%)	OR 95% CI p-value 1.36 0.77- 2.43 .292 1.38 0.80- 2.37 .247 1.56	n=34 ^a 31 (91.2%) 26 (76.5%)	OR 95% CI p-value 6.43* 1.91- 21.63* .003* 1.09* 1.78- 9.40* .001* 1.71	n=69 ^a 54 (78.3%) 43 (62.3%)	OR 95% CI p-value 2.24* 1.20- 4.20* .012* 2.08* 1.20- 3.60* .009* 1.87*	n=134 ^a 107 (79.9%) 87 (64.9%)	OR 95% CI p-value 2.47* 1.50- 4.04* <.001* 2.33* 1.51- 3.60* <.001* 1.02*
LBP ever LBP current LBP chronic	n= 247 ^a 151 (61.6%) 108 (44.3%) 83 (24.2%)	n=67 ^a 46 (68.7%) 35 (52.2%) 30 (44.8)	OR 95% CI p-value 1.36 0.77- 2.43 .292 1.38 0.80- 2.37 .247 1.56 0.90	n=34 ^a 31 (91.2%) 26 (76.5%) 16 (47.1%)	OR 95% CI p-value 6.43* 1.91- 21.63* .003* 1.09* 1.78- 9.40* .001* 1.71 0.82 2.52	n=69 ^a 54 (78.3%) 43 (62.3%) 34	OR 95% CI p-value 2.24* 1.20- 4.20* .012* 2.08* 1.20- 3.60* .009* 1.87* 1.08	n=134 ^a 107 (79.9%) 87 (64.9%) 67 (50.0%)	OR 95% CI p-value 2.47* 1.50- 4.04* <.001* 2.33* 1.51- 3.60* <.001* 1.93* 1.25
LBP ever LBP current LBP chronic	n= 247 ^a 151 (61.6%) 108 (44.3%) 83 (34.2%)	n=67 ^a 46 (68.7%) 35 (52.2%) 30 (44.8)	OR 95% CI p-value 1.36 0.77- 2.43 .292 1.38 0.80- 2.37 .247 1.56 0.90- 2.71	n=34 ^a 31 (91.2%) 26 (76.5%) 16 (47.1%)	OR 95% CI p-value 6.43* 1.91- 21.63* .003* 1.09* 1.78- 9.40* .001* 1.71 0.83-3.53 145	n=69 ^a 54 (78.3%) 43 (62.3%) 34 (49.3%)	OR 95% CI p-value 2.24* 1.20- 4.20* .012* 2.08* 1.20- 3.60* .009* 1.87* 1.08- 3.22*	n=134 ^a 107 (79.9%) 87 (64.9%) 67 (50.0%)	OR 95% CI p-value 2.47* 1.50- 4.04* <.001* 2.33* 1.51- 3.60* <.001* 1.93* 1.25- 2.96*
LBP ever LBP current LBP chronic	n= 247 ^a 151 (61.6%) 108 (44.3%) 83 (34.2%)	n=67 ^a 46 (68.7%) 35 (52.2%) 30 (44.8)	OR 95% CI p-value 1.36 0.77- 2.43 .292 1.38 0.80- 2.37 .247 1.56 0.90- 2.71 111	n=34 ^a 31 (91.2%) 26 (76.5%) 16 (47.1%)	OR 95% CI p-value 6.43* 1.91- 21.63* .003* 1.09* 1.78- 9.40* .001* 1.71 0.83-3.53 .145	n=69 ^a 54 (78.3%) 43 (62.3%) 34 (49.3%)	OR 95% CI p-value 2.24* 1.20- 4.20* .012* 2.08* 1.20- 3.60* .009* 1.87* 1.08- 3.22* 023*	n=134 ^a 107 (79.9%) 87 (64.9%) 67 (50.0%)	OR 95% CI p-value 2.47* 1.50- 4.04* <.001* 2.33* 1.51- 3.60* <.001* 1.93* 1.25- 2.96* 003*
LBP ever LBP current LBP chronic	n= 247 ^a 151 (61.6%) 108 (44.3%) 83 (34.2%) 32	n=67 ^a 46 (68.7%) 35 (52.2%) 30 (44.8) 13	OR 95% CI p-value 1.36 0.77- 2.43 .292 1.38 0.80- 2.37 .247 1.56 0.90- 2.71 .111 1.50	n=34 ^a 31 (91.2%) 26 (76.5%) 16 (47.1%) 8	OR 95% CI p-value 6.43* 1.91- 21.63* .003* 1.09* 1.78- 9.40* .001* 1.71 0.83-3.53 .145 2.13	n=69 ^a 54 (78.3%) 43 (62.3%) 34 (49.3%) 10	OR 95% CI p-value 2.24* 1.20- 4.20* .012* 2.08* 1.20- 3.60* .009* 1.87* 1.08- 3.22* .023* 1.05	n=134 ^a 107 (79.9%) 87 (64.9%) 67 (50.0%)	OR 95% CI p-value 2.47* 1.50- 4.04* <.001* 2.33* 1.51- 3.60* <.001* 1.93* 1.25- 2.96* .003* 1.01

(BMI>30)	(16.5%)	(22.8%)	0.72- 3.09 .277	(29.6%)	0.86-5.29 .103	(17.2%)	0.48- 2.30 .894	(16.7%)	0.54- 1.89 .969
Nulliparous	230	60	0.63	33	2.44	64	0.95	126	1.16
	(93.1%)	(89.6%)	0.25-	(97.1%)	0.31-	(92.8%)	0.34-	(94.0%)	0.49-
			1.60		18.94		2.66		2.77
			.333		.394		.916		.731
DASS depression	46	21	1.34* ^b	6	0.84 ^{c,e}	24	1.37* ^{b,c}	44	1.39* ^{b,c}
	(18.8%)	(31.8%)	1.08-	(17.7%)	0.32-2.19	(34.8%)	1.11-	(33.1%)	1.17-
			1.66*		.720		1.69*		1.66*
			.007*				.003*		<.001*
DASS anxiety	37	23	1.41* ^b	9	1.60 ^{c,e}	29	1.51* ^{b,c}	45	1.41* ^{b,c}
	(15.2%)	(34.9%)	1.13-	(26.5%)	0.67-3.82	(42.0%)	1.21-	(34.1%)	1.18-
			1.75*		.284		1.86*		1.68*
			.002*				<.001*		<.001*
DASS stress	31	21	1.47* ^b	8	2.01	21	1.52*	45	1.62* ^{b,c}
	(12.8%)	(31.3%)	1.15-	(25.5%)	0.81-4.99	(30.4%)	1.21-	(34.1%)	1.32-
			1.88*		.130		1.91*		1.98*
			.002*				<.001*		<.001*
SF12 PCS	54.2	52.1	0.97	52.3	0.98	51.5	0.97	51.7	0.97
(mean, SD)	(6.6)	(8.4)	0.93-	(7.4)	0.94-1.03	(9.3)	0.93-	(8.7)	0.94-
			1.00		.467		1.00		1.00
			.063				.056		.051
SF12 MCS	46.5	42.7	0.97*	44.0	0.99	41.5	0.97*	41.0	0.96*
(mean, SD)	(10.7)	(11.4)	0.95-	(9.9)	0.96-1.02	(11.5)	0.94-	(10.5)	0.94-
			0.99*		.529		0.99*		0.98*
			.013*				.005*		<.001*

508 UG urogenital, UUI urinary urge incontinence, SUI stress urinary incontinence, MUI mixed urinary incontinence, leakage of small drops small drops of urinary leakage, difficulty emptying difficulty emptying the bladder, pain urogenital pain, LBP

509 low back pain, DASS Depression Anxiety Stress Scale short version, SF-12 Short Form 12 Health Survey, PCS physical component score, MCS mental component score

510 *statistically significant odds ratios

³percentages for independent variables are column percentages with number available for analysis with/without UG symptom as the denominator

⁵¹² ^bOdds Ratio represents proportional increase in odds for UG symptom for 1 increment of the 5 categories (none, mild, moderate, severe, extremely severe)

513 of DASS-21 score. (descriptives collapsed by moderate of more presented for brevity)

- 514 ^cadjusted for current LBP
- ^dOdds Ratio represents proportional decrease in odds for UG symptom for each increment of 1 in SF score.
- ⁶Categories collapsed due to sparse cells. Odds Ratio presents proportional increase in odds for UG symptom for category (moderate, severe, extremely
- 517 severe) compared to category (none, mild) of DASS-21 score.

- 52: